TSE:ONC Oncolytics Biotech (ONC) Stock Forecast, Price & News C$2.28 +0.04 (+1.79%) (As of 06/2/2023 ET) Add Compare Share Share Today's RangeC$2.21▼C$2.3050-Day RangeC$1.51▼C$2.9352-Week RangeC$1.06▼C$3.10Volume103,672 shsAverage Volume55,145 shsMarket CapitalizationC$146.13 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Oncolytics Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside196.1% UpsideC$6.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 stars 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$6.75, Oncolytics Biotech has a forecasted upside of 196.1% from its current price of C$2.28.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ONC. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONC. Previous Next 1.4 News and Social Media Coverage News SentimentOncolytics Biotech has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.34% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 1.47% of the stock of Oncolytics Biotech is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oncolytics Biotech (TSE:ONC) StockOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesMay 31, 2023 | baystreet.caSignificant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023May 27, 2023 | americanbankingnews.comOncolytics Biotech (TSE:ONC) PT Set at C$9.00 by JonestradingJune 3, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 26, 2023 | msn.comOncolytics Biotech Dives after Breast Cancer Treatment DisappointsMay 26, 2023 | msn.comOncolytics falls 16% after mid-stage data for breast cancer therapyMay 26, 2023 | finanznachrichten.deUSA News Group: Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral PresentationsMay 25, 2023 | finance.yahoo.comOncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting AbstractMay 24, 2023 | finance.yahoo.comCANADA STOCKS-TSX tumbles as bank earnings, US debt deal uncertainty weighJune 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 24, 2023 | baystreet.caTSX Sinks into the RedMay 24, 2023 | benzinga.comOncolytics Biotech shares are trading higher after JonesTrading initiated covered on the stock with a Buy rating and announced a $9 price target.May 21, 2023 | americanbankingnews.comOncolytics Biotech (TSE:ONC) Stock Price Passes Above Two Hundred Day Moving Average of $2.09May 13, 2023 | americanbankingnews.comFY2027 EPS Estimates for Oncolytics Biotech Inc. (TSE:ONC) Increased by AnalystMay 12, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Oncolytics Biotech Inc. (TSE:ONC) Issued By HC WainwrightMay 10, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersMay 9, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY) and Senseonics Holdings (SENS)May 7, 2023 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call TranscriptMay 6, 2023 | ca.finance.yahoo.comStocks in play: Oncolytics BiotechMay 5, 2023 | benzinga.comOncolytics Biotech Says Cash Balance Of C$29.7M Is Expected To Provide Projected Cash Runway For At Least 12 MonthsMay 5, 2023 | msn.comOncolytics Biotech: Q1 Earnings InsightsMay 5, 2023 | finance.yahoo.comOncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational HighlightsMay 4, 2023 | americanbankingnews.comOncolytics Biotech (ONC) Set to Announce Quarterly Earnings on FridayMay 3, 2023 | marketwatch.comOncolytic Virus Therapy Market : Competitive Strategy Analysis and Forecast Values 2023-2031April 27, 2023 | marketwatch.comGlobal Oncolytic Virus Therapy Market by [2023-2029] with Revenue OutsourcingApril 26, 2023 | finance.yahoo.comOncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual MeetingApril 25, 2023 | markets.businessinsider.comOncolytic Virus Therapies Market Size Worth USD 609.7 Million in 2028 - Emergen ResearchApril 12, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual ConferenceSee More Headlines ONC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Company Calendar Today6/02/2023Next Earnings (Estimated)8/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$6.75 High Stock Price ForecastC$9.00 Low Stock Price ForecastC$3.00 Forecasted Upside/Downside+196.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-24,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.61% Return on Assets-42.85% Debt Debt-to-Equity Ratio2.20 Current Ratio13.88 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.54 per share Price / Cash Flow4.22 Book ValueC$0.40 per share Price / Book5.70Miscellaneous Outstanding Shares64,090,000Free FloatN/AMarket CapC$146.13 million OptionableNot Optionable Beta1.79 Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., Pres, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerMr. Andrew R. de Guttadauro (Age 55)Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc Comp: $558.94kDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., VP of Product Devel.Jon PattonDirector of Investor Relations & CommunicationDr. Grey Wilkinson Ph.D.Scientist of Translational MedicineMr. John Mark Lievonen F.C.A.FCA, ConsultantDr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)FACP, M.D., Consultant More ExecutivesKey CompetitorsImmunoPrecise AntibodiesCVE:IPABriaCell TherapeuticsCVE:BCTTheratechnologiesTSE:THScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMView All CompetitorsInsidersAllison HagermanBought 4,200 shares on 6/16/2022Total: C$4,851.00 ($1.16/share)Matthew CoffeyBought 5,774 shares on 6/14/2022Total: C$6,219.46 ($1.08/share)Kirk LookBought 6,000 shares on 6/14/2022Total: C$6,656.40 ($1.11/share)View All Insider Transactions ONC Stock - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price forecast for 2023? 5 brokers have issued 1 year price targets for Oncolytics Biotech's shares. Their ONC share price forecasts range from C$3.00 to C$9.00. On average, they expect the company's share price to reach C$6.75 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts. How have ONC shares performed in 2023? Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have increased by 2.7% and is now trading at C$2.28. View the best growth stocks for 2023 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ONC earnings forecast. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR). What is Oncolytics Biotech's stock symbol? Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC." How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Oncolytics Biotech's stock price today? One share of ONC stock can currently be purchased for approximately C$2.28. How much money does Oncolytics Biotech make? Oncolytics Biotech (TSE:ONC) has a market capitalization of C$146.13 million. The company earns C$-24,490,000.00 in net income (profit) each year or C($0.42) on an earnings per share basis. How can I contact Oncolytics Biotech? Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380. This page (TSE:ONC) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.